{"id":4335,"date":"2026-11-14T09:00:00","date_gmt":"2026-11-14T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4335"},"modified":"2026-11-14T12:51:49","modified_gmt":"2026-11-14T16:51:49","slug":"saturday-rounds-week-of-november-7-13-2026","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4335","title":{"rendered":"Saturday Rounds: Week of November 7\u201313, 2026"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261114_Insilens_Saturday_Rounds-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4336\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261114_Insilens_Saturday_Rounds-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261114_Insilens_Saturday_Rounds-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261114_Insilens_Saturday_Rounds-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261114_Insilens_Saturday_Rounds-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261114_Insilens_Saturday_Rounds.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Base editing reaches the pivotal gate.<\/strong><\/p>\n<p>Weekly Biotech Signal Review \u00b7 Completed reporting week: November 7\u2013November 13, 2026 \u00b7 Published November 14, 2026<\/p>\n<p><strong>Report at a glance:<\/strong> Beam\u2019s risto-cel met its pivotal sickle cell endpoint without a published responder count, the FDA approved the first factor XIa inhibitor, and argenx, Pfizer, MaxCyte and Vor committed capital to defined bets, while XBI slipped 1.09% and Cellectis cut up to 70% of its workforce.<\/p>\n<h3>The Lede<\/h3>\n<p>Beam Therapeutics reported on November 10 that the Phase 1\/2 BEACON trial of risto-cel in sickle cell disease met its primary efficacy endpoint, freedom from severe vaso-occlusive crises for at least 12 consecutive months at a prespecified interim analysis, and all primary safety endpoints. As of the October data cutoff 49 patients had been treated (39 adults, 10 adolescents) and 31 had completed follow-up for the primary endpoint. Beam plans a BLA as early as year-end 2026, which would be the first for a base-edited therapy. Detailed numbers are withheld: the responder count, confidence intervals and a full adverse-event table are not public, and more data are planned for ASH in December and a 2027 meeting.<\/p>\n<table>\n<thead>\n<tr>\n<th>Signal Importance<\/th>\n<th>Signal Direction<\/th>\n<th>Confidence in Facts<\/th>\n<th>Confidence in Interpretation<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>5 \/ 5<\/td>\n<td>Cautiously positive on endpoint attainment; uncertain on comparative benefit<\/td>\n<td>High<\/td>\n<td>Moderate-low<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Weekly validation gate: importance is 5\/5 because a pivotal hematology endpoint now has a near-term regulatory path. Interpretation is moderate-low because Beam has published no responder numerator, intervals, baseline event distribution or durability data, and the result is a single-arm, company-reported topline.<\/em><\/p>\n<h3>Signal of the Week: Risto-cel Meets Its Pivotal Endpoint<\/h3>\n<p>The result matters because it moves base editing from platform promise toward registration in a disease where exa-cel and lovo-cel already exist. If the full dataset confirms a high VF12 responder rate, durable fetal-hemoglobin induction, stable engraftment and no late clonal or genotoxic signal, Beam could compete on editing precision and manufacturing execution. Beam\u2019s guidance is that safety, response rates and longer-term outcomes are the next disclosures.<\/p>\n<p>The strongest counterargument is structural: every autologous HSC approach still needs cell collection, conditioning and specialist centers, and with 31 endpoint-mature patients and no published numerator, a comparison with exa-cel, lovo-cel or transplant is not yet possible. The reference file describes the endpoint as independently adjudicated; we could not confirm that detail and have not repeated it.<\/p>\n<h3>The Week in Five<\/h3>\n<p><strong>Regulatory<\/strong> \u2014 The FDA approved Bayer\u2019s asundexian (Sunharbo) with antiplatelet therapy for adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk TIA, the first factor XIa inhibitor cleared in the US; in OCEANIC-STROKE ischemic stroke occurred in 6.2% versus 8.4% on placebo (hazard ratio 0.74) with similar major bleeding (1.9% versus 1.7%). It is not approved for atrial fibrillation, and shipping is expected in mid-to-late November. In China, the NMPA approved Hengrui\u2019s ANGPTL3 antibody for homozygous familial hypercholesterolemia and, on November 12, Lilly\u2019s oral orforglipron for adult weight management.<\/p>\n<p><strong>Clinical<\/strong> \u2014 Risto-cel (above). The reference file\u2019s autoimmune CAR-T and NK-cell datasets (CRISPR Therapeutics, Cabaletta, Nkarta, IASO) were not individually verified for this edition and are not reported.<\/p>\n<p><strong>Deals<\/strong> \u2014 argenx agreed (November 9) to acquire the rest of Unnatural Products, in which it already held a minority stake, for $550 million in upfront cash plus up to $595 million in milestones (about $1.15 billion total), closing expected by year-end. Pfizer announced that Blackstone Life Sciences will fund up to $1.5 billion of berobenatide (the Metsera-derived monthly GLP-1) development costs through 2028 in return for milestones tied to US approval and sales targets; Blackstone gets no rights and no development role. MaxCyte agreed to acquire Akron Bio for about $151.8 million ($105 million cash, 20.6 million new shares and $20 million deferred). Vor Bio added RemeGen\u2019s dual BAFF\/APRIL antibody RC298 outside Greater China for about $56 million upfront ($10 million cash plus a pre-funded warrant for 2.3 million shares) and up to $300 million in development milestones.<\/p>\n<p><strong>Platform<\/strong> \u2014 A Nature paper describes domain-alteration chimeras (DALTACs) that force proximity between the androgen receptor and p300\/CBP to suppress oncogenic transcription in prostate cancer models without degrading either protein. The evidence is preclinical; treatment readiness is unproven.<\/p>\n<p><strong>China<\/strong> \u2014 Hengrui\u2019s HoFH approval and the NMPA\u2019s orforglipron approval are the week\u2019s China regulatory actions, and Vor\u2019s RC298 license extends the pattern of China-origin autoimmune assets licensed ex-China (RemeGen retains Greater China rights; its first China filing is expected in the first half of 2027).<\/p>\n<h3>The Analyst\u2019s Take<\/h3>\n<p>Observed pattern: evidence maturity showed up in the week\u2019s outcomes. Beam crossed a pivotal gate, Bayer converted a randomized stroke trial into the first US factor XIa approval, and Hengrui converted ANGPTL3 biology into a rare-disease approval in China. Capital followed defined next steps: argenx paid cash for a platform it already held an option on, Pfizer used external development financing instead of selling control, and Vor structured an asset addition around a small cash upfront.<\/p>\n<p>Explicit inference: platform breadth is being funded when it attaches to a measurable next experiment, while infrastructure-heavy programs without a near registration path face pruning, as Cellectis\u2019 decision to exit its two allogeneic CAR-T programs and cut up to 70% of headcount illustrates. A competing interpretation is cyclical: an open financing window and a dense conference calendar may explain the clustering, and Cellectis may be a balance-sheet-specific decision. The thesis strengthens if milestone structures and follow-on financing keep tracking human pharmacology; it weakens if preclinical platforms raise on equal terms without translational proof.<\/p>\n<h3>Evidence Classification<\/h3>\n<table>\n<thead>\n<tr>\n<th>Verified facts<\/th>\n<th>Company claims<\/th>\n<th>Explicit inference<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>The risto-cel topline structure and patient counts, the asundexian label and OCEANIC-STROKE numbers, both China approvals, argenx, Pfizer\u2013Blackstone, MaxCyte and Vor terms, Cellectis\u2019 restructuring, the Prime and Windward financings and the XBI closes were checked against company releases, SEC-linked sources and named trade press.<\/td>\n<td>Beam\u2019s \u201cpositive\u201d characterization and plan to file as early as year-end, Bayer\u2019s launch timing, Pfizer\u2019s and Blackstone\u2019s description of the financing terms, and Cellectis\u2019 runway guidance are sponsor statements.<\/td>\n<td>\u201cEvidence maturity is becoming commercially visible\u201d and the reading of financing structures as risk deferral are interpretations.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Market &amp; Capital Pulse<\/h3>\n<p><strong>Observed market facts<\/strong><\/p>\n<p>Measurement window: Friday, November 6 close to Friday, November 13 close. XBI fell 1.09% (152.21 to 150.55). XBI closed at 156.31 on Wednesday, November 11, so the week\u2019s loss came late. For SPY, sources conflict: Yahoo\u2019s quote page shows 754.37 for November 13 and its history table shows 758.91; against the reference file\u2019s November 6 figure of 735.29 (not independently verified) that implies a gain of roughly 2.6% to 3.2%. We could not confirm an IBB close for November 13 (iShares shows a November 12 close of 213.43 and a November 13 NAV of 212.49), so no IBB weekly figure is reported. On any of the SPY readings, XBI underperformed the broad market by roughly 3.7 points or more; these returns show relative weakness, not its cause.<\/p>\n<p><strong>Capital and strategic appetite<\/strong><\/p>\n<p>Public markets: Prime Medicine closed an underwritten offering of 41.07 million shares at $3.50, $143.7 million gross including the full underwriter option. Windward Bio priced a $175 million US IPO (about 10.3 million shares at $17, within the $16 to $18 range), began trading on November 13 under WWB, and sold a further $50 million of shares to Sanofi in a concurrent private placement; Citeline counts it as the 30th US biopharma IPO this year. The reference file expects both to close on November 16, which we could not confirm, so they are not counted as completed proceeds. Private rounds in the reference file (seed, Series A and B rounds) were not verified and are not reported.<\/p>\n<p>Inference, not causation: capital was available to programs with clinical maturity, strategic sponsorship or a specific platform experiment, but a single week cannot separate that selectivity from market beta.<\/p>\n<h3>Deal Appetite and Restructuring<\/h3>\n<p>Four transactions carried verified terms. Cash at signing or closing totals about $665 million ($550 million argenx, $105 million MaxCyte, $10 million Vor), with $20 million of guaranteed deferred payments (MaxCyte) and about $895 million of contingent milestones ($595 million argenx, $300 million Vor). Pfizer\u2013Blackstone is separate: up to $1.5 billion of development funding paid to Pfizer, contingent on development spend, not a purchase price. Share and warrant consideration (MaxCyte\u2019s 20.6 million shares, about $26.8 million at the November 9 close; Vor\u2019s pre-funded warrant) is excluded from the cash total.<\/p>\n<p>Restructuring: Cellectis expects headcount to fall by up to 70% over 2026 and 2027, subject to French works council consultation, as it exits lasme-cel and eti-cel and focuses on in vivo candidates HEAL-101 and HEAL-201; it reported $149 million of cash and term deposits at September 30 and a $61.5 million third-quarter net loss. Note that the strategic transformation was announced on September 14; the November 13 reporting restates and updates it. The reference file\u2019s eight leadership changes could not be verified and none are reported.<\/p>\n<h3>By the Numbers<\/h3>\n<table>\n<thead>\n<tr>\n<th>Category<\/th>\n<th>Verified count or value<\/th>\n<th>Scope note<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Approvals<\/td>\n<td>3<\/td>\n<td>FDA: asundexian. China: Hengrui HoFH antibody (named rivocibart in sources; the reference file says \u201crevocimab\u201d); Lilly orforglipron.<\/td>\n<\/tr>\n<tr>\n<td>Pivotal readouts<\/td>\n<td>1<\/td>\n<td>Beam risto-cel BEACON topline (company-reported).<\/td>\n<\/tr>\n<tr>\n<td>Acquisitions signed<\/td>\n<td>2<\/td>\n<td>argenx\u2013Unnatural Products ($550M upfront; up to $1.15B); MaxCyte\u2013Akron Bio ($151.8M). Neither closed.<\/td>\n<\/tr>\n<tr>\n<td>License \/ financing deals<\/td>\n<td>2<\/td>\n<td>Vor\u2013RemeGen RC298 (~$56M upfront incl. warrant; up to $300M); Pfizer\u2013Blackstone (up to $1.5B development funding).<\/td>\n<\/tr>\n<tr>\n<td>Public financings<\/td>\n<td>2 \/ about $318.7M gross<\/td>\n<td>Prime $143.7M follow-on (closed); Windward $175M IPO priced (excludes $50M Sanofi placement; closing not confirmed).<\/td>\n<\/tr>\n<tr>\n<td>Material restructurings<\/td>\n<td>1<\/td>\n<td>Cellectis, up to 70% workforce reduction.<\/td>\n<\/tr>\n<tr>\n<td>Private rounds, leadership changes, human-data counts<\/td>\n<td>Not verified<\/td>\n<td>Reference-file figures (28 updates, 8 leaders, 12 papers) were not independently confirmed.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Watching Next Week<\/h3>\n<p>Resolution of last week\u2019s calendar: ivonescimab\u2019s PDUFA goal date (Summit, EGFR-mutated NSCLC) fell on November 14; we found no reported FDA decision as of this edition, and sources conflict on how strong the supporting survival data are. CTX310\u2019s AHA presentation date and the Karyopharm court milestones were not verified.<\/p>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Catalyst<\/th>\n<th>Evidence status<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Nov 14<\/td>\n<td>Ivonescimab PDUFA goal date (Summit)<\/td>\n<td>Date confirmed in Summit\u2019s BLA acceptance release; outcome pending.<\/td>\n<\/tr>\n<tr>\n<td>Nov 16<\/td>\n<td>Windward Bio IPO and Sanofi placement scheduled to close<\/td>\n<td>From the reference file; not independently confirmed.<\/td>\n<\/tr>\n<tr>\n<td>Nov 16<\/td>\n<td>Roche trontinemab Brainshuttle Phase Ib\/IIa symposium at CTAD, 4:50 p.m.<\/td>\n<td>Confirmed in Roche\u2019s CTAD release.<\/td>\n<\/tr>\n<tr>\n<td>Nov 16\u201319<\/td>\n<td>CTAD 2026 (Boston): Biogen\/Eisai lecanemab five-year Clarity AD extension findings; Biogen diranersen 96-week extension data<\/td>\n<td>Confirmed in Biogen\u2019s CTAD release; session days and times not confirmed.<\/td>\n<\/tr>\n<tr>\n<td>Nov 16\u201319<\/td>\n<td>Acadia remlifanserin Alzheimer\u2019s psychosis presentation (oral OC05)<\/td>\n<td>Listed in the CTAD preliminary program; time and RADIANT detail not confirmed.<\/td>\n<\/tr>\n<tr>\n<td>Dec 2026<\/td>\n<td>Beam risto-cel data at ASH; BLA as early as year-end<\/td>\n<td>Company guidance.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>What Would Change Our View<\/h3>\n<p><strong>Upgrade<\/strong> \u2014 A complete risto-cel dataset showing a high VF12 responder rate, durable engraftment and fetal hemoglobin, reproducible manufacturing and no late clonal signal would strengthen the evidence-weighted displacement thesis.<\/p>\n<p><strong>Downgrade<\/strong> \u2014 Efficacy comparable to existing therapies without a clear advantage in safety, conditioning, turnaround or access, or further program retrenchment after financing, would weaken the case that editing precision translates into competitive advantage.<\/p>\n<p><strong>Falsify<\/strong> \u2014 If capital and licensing terms over the next several quarters fail to differentiate controlled human evidence from attractive preclinical mechanisms, the thesis that funding is becoming more evidence-weighted would be falsified.<\/p>\n<h3>Evidence Base<\/h3>\n<p><em>Sources are listed in order of first citation. Discrepancies versus the reference file used for this edition: the XBI closes (152.21 and 150.55) were confirmed, but SPY\u2019s November 13 close is 754.37 on one Yahoo page and 758.91 on another, and the IBB closes (213.63, 212.50) could not be confirmed; Hengrui\u2019s drug is called rivocibart in sources, not \u201crevocimab\u201d; Windward\u2019s pricing date and November 16 closing could not be confirmed (sources say the IPO began trading on November 13); the reference file\u2019s \u201cindependently adjudicated\u201d endpoint description for risto-cel was not found in sources; Pfizer\u2013Blackstone was dated November 11 or 12 by different outlets and one outlet cited $2 billion against $1.5 billion elsewhere. Left out as unverified: Cellectis\u2019 \u201cstopped enrollment\u201d wording (sources say it will exit two allogeneic programs), the 28 readouts, 8 leadership changes and 12 papers counts, the private rounds, and the CTAD times for Biogen and Acadia.<\/em><\/p>\n<ol>\n<li><a href=\"https:\/\/investors.beamtx.com\/news-releases\/news-release-details\/beam-therapeutics-announces-positive-topline-pivotal-data-beacon\">Beam Therapeutics, Positive Topline Pivotal Data from BEACON Phase 1\/2 Trial of Risto-cel<\/a><\/li>\n<li><a href=\"https:\/\/www.biospace.com\/drug-development\/beam-preps-fda-run-for-industry-first-base-edited-therapy-after-pivotal-sickle-cell-success\">BioSpace, Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success<\/a><\/li>\n<li><a href=\"https:\/\/www.rttnews.com\/3712610\/beam-reports-positive-pivotal-results-for-gene-edited-sickle-cell-therapy-risto-cel.aspx\">RTTNews, Beam Reports Positive Pivotal Results For Gene-Edited Sickle Cell Therapy Risto-cel<\/a><\/li>\n<li><a href=\"https:\/\/medcitynews.com\/2026\/11\/bayer-sunharbo-asundexian-fda-approval-secondary-stroke-prevention-factor-xia-bayry\/\">MedCity News, FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke<\/a><\/li>\n<li><a href=\"https:\/\/endpoints.news\/bayer-wins-fda-approval-for-stroke-prevention-drug-sunharbo\/\">Endpoints News, Bayer wins FDA approval for stroke prevention drug with blockbuster potential<\/a><\/li>\n<li><a href=\"https:\/\/allsci.com\/news\/approvals\/hengrui-rivocibart-nmpa-approves-hengruis-for\/\">AllSci, Hengrui wins China approval for ANGPTL3 antibody after 64% LDL-C advantage in Phase III HoFH trial<\/a><\/li>\n<li><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/eli-lilly-oral-glp1-ra-foundayo-nmpa-approval-weight-management\/\">Pharmaceutical Technology, Eli Lilly beats Novo to oral China GLP-1RA market on NMPA approval<\/a><\/li>\n<li><a href=\"https:\/\/www.globenewswire.com\/news-release\/2026\/11\/09\/3398043\/0\/en\/unnatural-products-to-be-acquired-by-argenx-for-up-to-1-15-billion-to-advance-next-generation-medicines.html\">argenx, Unnatural Products to be Acquired by argenx for up to $1.15 Billion (GlobeNewswire, Nov 9, 2026)<\/a><\/li>\n<li><a href=\"https:\/\/www.biospace.com\/business\/pfizer-snags-1-5b-financing-from-pe-firm-blackstone-to-support-metsera-asset\">BioSpace, Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset<\/a><\/li>\n<li><a href=\"https:\/\/www.biopharminternational.com\/view\/blackstone-to-provide-pfizer-up-to-1-5-billion-for-monthly-glp-1-berobenatide-development\">BioPharma International, Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development<\/a><\/li>\n<li><a href=\"https:\/\/www.manilatimes.net\/2026\/11\/10\/tmt-newswire\/globenewswire\/maxcyte-to-acquire-akron-bio-expanding-its-offerings-across-cell-therapy-manufacturing-and-expecting-to-nearly-double-revenue-base\/2466187\">MaxCyte, to Acquire Akron Bio (Manila Times\/GlobeNewswire, Nov 10, 2026)<\/a><\/li>\n<li><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001287098\/000110465926124829\/tm2629420d1_8k.htm\">MaxCyte, Form 8-K (SEC)<\/a><\/li>\n<li><a href=\"https:\/\/www.thepharmaletter.com\/biotech-news\/vor-bio-expands-strategic-partnership-with-remegen\">The Pharma Letter, Vor Bio expands strategic partnership with RemeGen<\/a><\/li>\n<li><a href=\"https:\/\/www.tradingview.com\/news\/tradingview:2401f33e613a5:0-vor-biopharma-adds-rc298-to-remegen-license-for-10-million-and-a-2-3-million-share-warrant\/\">TradingView, Vor Biopharma Adds RC298 to RemeGen License for $10 Million and a 2.3 Million-Share Warrant<\/a><\/li>\n<li><a href=\"https:\/\/www.nature.com\/articles\/s41586-026-11262-4\">Nature, Domain-alteration chimeras rewire oncogenic complexes in prostate cancer<\/a><\/li>\n<li><a href=\"https:\/\/www.fiercebiotech.com\/biotech\/cellectis-will-shed-70-workforce-part-vivo-pivot\">Fierce Biotech, Cellectis will shed 70% of workforce as part of in vivo pivot<\/a><\/li>\n<li><a href=\"https:\/\/www.biospace.com\/job-trends\/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies\">BioSpace, Cellectis could cut 70% of workforce in shift to in vivo therapies<\/a><\/li>\n<li><a href=\"https:\/\/www.stocktitan.net\/news\/PRME\/prime-medicine-announces-closing-of-public-offering-and-full-4px3oy2gyd4t.html\">Stock Titan, Prime Medicine closes ~$143.7M gross stock offering<\/a><\/li>\n<li><a href=\"https:\/\/finance.yahoo.com\/healthcare\/articles\/windward-prices-175m-ipo-advance-012200131.html\">Yahoo Finance, Windward prices $175M IPO to advance China-licensed lung drugs<\/a><\/li>\n<li><a href=\"https:\/\/insights.citeline.com\/scrip\/business\/financing\/finance-watch\/finance-watch-biopharma-ipo-tally-reaches-30-in-the-us-FWD4I44PWREAZBC2YODSETD6NQ\/\">Citeline Scrip, Finance Watch: Biopharma IPO Tally Reaches 30 In The US<\/a><\/li>\n<li><a href=\"https:\/\/finance.yahoo.com\/quote\/XBI\/history\/\">Yahoo Finance, XBI quote and history<\/a><\/li>\n<li><a href=\"https:\/\/finance.yahoo.com\/quote\/SPY\/history\/\">Yahoo Finance, SPY quote and history<\/a><\/li>\n<li><a href=\"https:\/\/www.ishares.com\/us\/products\/239699\/ishares-biotechnology-etf\">iShares, Biotechnology ETF (IBB) fund page<\/a><\/li>\n<li><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260129109846\/en\/Summit-Therapeutics-Announces-U.S.-FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy\">Summit Therapeutics, FDA Acceptance of Ivonescimab BLA (PDUFA Nov 14, 2026)<\/a><\/li>\n<li><a href=\"https:\/\/www.globenewswire.com\/news-release\/2026\/11\/10\/3399142\/0\/en\/roche-presents-new-data-across-pharmaceuticals-and-diagnostics-from-its-growing-alzheimer-s-disease-portfolio-at-ctad-2026.html\">Roche, New data from its Alzheimer\u2019s disease portfolio at CTAD 2026 (GlobeNewswire, Nov 10, 2026)<\/a><\/li>\n<li><a href=\"https:\/\/www.globenewswire.com\/news-release\/2026\/10\/29\/3391082\/0\/en\/biogen-to-present-new-data-across-alzheimer-s-disease-portfolio-at-ctad-2026.html\">Biogen, New Data Across Alzheimer\u2019s Disease Portfolio at CTAD 2026 (GlobeNewswire, Oct 29, 2026)<\/a><\/li>\n<li><a href=\"https:\/\/www.ctad-alzheimer.com\/sites\/www.ctad-alzheimer.com\/files\/medias\/documents\/CTAD26_Preliminary%20Program1.pdf\">CTAD 2026, Preliminary Program<\/a><\/li>\n<\/ol>\n<p>Until next Saturday: follow the evidence, not the noise.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Base editing reaches the pivotal gate. Weekly Biotech Signal Review \u00b7 Completed reporting week: November 7\u2013November 13, 2026 \u00b7 Published November 14, 2026 Report at a glance: Beam\u2019s risto-cel met its pivotal sickle cell&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4336,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[250,251,249],"class_list":["post-4335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weekly-market-insight","tag-biotech-markets","tag-ma","tag-weekly-digest"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4335"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4335\/revisions"}],"predecessor-version":[{"id":4337,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4335\/revisions\/4337"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4336"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}